Birdwatch Note
2025-02-13 20:06:55 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
El dolutegravir disminuye la cantidad de VIH en la sangre pero no cura el VIH, con otros medicamentos puede reducir la posibilidad de SIDA y es de licencia obligatoria en Colombia por Resolución 20049 del 23 de abril de 2024, medida tomada por Minsalud y la SIC. https://medlineplus.gov/spanish/druginfo/meds/a613043-es.html https://www.minsalud.gov.co/Paginas/SIC-confirma-la-licencia-obligatoria-otorgada-a-minsalud-sobre-Dolutegravir.aspx#:~:text=SIDA%20en%20Colombia-,Superintendencia%20de%20Industria%20y%20Comercio%20confirma%20la%20licencia%20obligatoria%20otorgada,con%20VIH/SIDA%20en%20Colombia
Written by E464B37C7F97DE897938FDF0E7D0024F88E62CCDC9DE3A4F651377EFA70C77F9
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1890099382575382641
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1890130552377794651
- noteId - 1890130552377794651
- participantId -
- noteAuthorParticipantId - E464B37C7F97DE897938FDF0E7D0024F88E62CCDC9DE3A4F651377EFA70C77F9
- createdAtMillis - 1739477215271
- tweetId - 1890099382575382641
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- El dolutegravir disminuye la cantidad de VIH en la sangre pero no cura el VIH, con otros medicamentos puede reducir la posibilidad de SIDA y es de licencia obligatoria en Colombia por Resolución 20049 del 23 de abril de 2024, medida tomada por Minsalud y la SIC. https://medlineplus.gov/spanish/druginfo/meds/a613043-es.html https://www.minsalud.gov.co/Paginas/SIC-confirma-la-licencia-obligatoria-otorgada-a-minsalud-sobre-Dolutegravir.aspx#:~:text=SIDA%20en%20Colombia-,Superintendencia%20de%20Industria%20y%20Comercio%20confirma%20la%20licencia%20obligatoria%20otorgada,con%20VIH/SIDA%20en%20Colombia
Note Ratings
| rated at | rated by | |
| 2025-02-14 17:34:20 -0600 | Rating Details | |
| 2025-02-14 16:53:44 -0600 | Rating Details | |
| 2025-02-14 16:37:16 -0600 | Rating Details | |
| 2025-02-14 16:23:57 -0600 | Rating Details | |
| 2025-02-14 10:40:18 -0600 | Rating Details | |
| 2025-02-14 08:51:17 -0600 | Rating Details | |
| 2025-02-14 08:36:58 -0600 | Rating Details | |
| 2025-02-14 07:54:08 -0600 | Rating Details | |
| 2025-02-14 07:50:57 -0600 | Rating Details | |
| 2025-02-14 06:35:54 -0600 | Rating Details | |
| 2025-02-14 06:34:08 -0600 | Rating Details | |
| 2025-02-14 06:08:04 -0600 | Rating Details | |
| 2025-02-14 05:21:39 -0600 | Rating Details | |
| 2025-02-14 04:25:29 -0600 | Rating Details | |
| 2025-02-14 02:36:22 -0600 | Rating Details | |
| 2025-02-14 01:32:40 -0600 | Rating Details | |
| 2025-02-14 01:20:14 -0600 | Rating Details | |
| 2025-02-13 23:46:05 -0600 | Rating Details | |
| 2025-02-13 23:33:36 -0600 | Rating Details | |
| 2025-02-13 22:45:33 -0600 | Rating Details | |
| 2025-02-13 22:38:40 -0600 | Rating Details | |
| 2025-02-13 21:43:27 -0600 | Rating Details | |
| 2025-02-13 21:41:54 -0600 | Rating Details | |
| 2025-02-13 21:05:03 -0600 | Rating Details | |
| 2025-02-13 20:49:20 -0600 | Rating Details | |
| 2025-02-13 20:17:36 -0600 | Rating Details | |
| 2025-02-13 20:01:44 -0600 | Rating Details | |
| 2025-02-13 19:52:43 -0600 | Rating Details | |
| 2025-02-13 19:49:48 -0600 | Rating Details | |
| 2025-02-13 19:00:20 -0600 | Rating Details | |
| 2025-02-13 18:03:54 -0600 | Rating Details | |
| 2025-02-13 17:58:28 -0600 | Rating Details | |
| 2025-02-13 17:58:00 -0600 | Rating Details | |
| 2025-02-13 17:57:25 -0600 | Rating Details | |
| 2025-02-13 17:46:57 -0600 | Rating Details | |
| 2025-02-13 17:46:23 -0600 | Rating Details | |
| 2025-02-13 17:41:52 -0600 | Rating Details | |
| 2025-02-13 17:12:18 -0600 | Rating Details | |
| 2025-02-13 17:11:04 -0600 | Rating Details | |
| 2025-02-13 16:50:27 -0600 | Rating Details | |
| 2025-02-13 16:28:01 -0600 | Rating Details | |
| 2025-02-13 16:25:30 -0600 | Rating Details | |
| 2025-02-13 16:20:53 -0600 | Rating Details | |
| 2025-02-13 16:20:27 -0600 | Rating Details | |
| 2025-02-13 16:19:57 -0600 | Rating Details | |
| 2025-02-13 16:18:03 -0600 | Rating Details | |
| 2025-02-13 16:16:15 -0600 | Rating Details | |
| 2025-02-13 16:15:14 -0600 | Rating Details | |
| 2025-02-13 16:15:03 -0600 | Rating Details | |
| 2025-02-13 16:08:30 -0600 | Rating Details | |
| 2025-02-13 16:03:13 -0600 | Rating Details | |
| 2025-02-13 15:59:55 -0600 | Rating Details | |
| 2025-02-13 15:59:36 -0600 | Rating Details | |
| 2025-02-13 15:59:26 -0600 | Rating Details | |
| 2025-02-13 15:56:01 -0600 | Rating Details | |
| 2025-02-13 15:54:14 -0600 | Rating Details | |
| 2025-02-13 15:47:37 -0600 | Rating Details | |
| 2025-02-13 15:47:00 -0600 | Rating Details | |
| 2025-02-13 15:43:49 -0600 | Rating Details | |
| 2025-02-13 15:34:55 -0600 | Rating Details | |
| 2025-02-13 15:33:24 -0600 | Rating Details | |
| 2025-02-13 15:19:19 -0600 | Rating Details | |
| 2025-02-13 15:17:36 -0600 | Rating Details | |
| 2025-02-13 15:17:06 -0600 | Rating Details | |
| 2025-02-13 15:15:53 -0600 | Rating Details | |
| 2025-02-13 15:11:00 -0600 | Rating Details | |
| 2025-02-13 15:09:22 -0600 | Rating Details | |
| 2025-02-13 15:07:48 -0600 | Rating Details | |
| 2025-02-13 15:02:37 -0600 | Rating Details | |
| 2025-02-13 14:58:29 -0600 | Rating Details | |
| 2025-02-13 14:51:51 -0600 | Rating Details | |
| 2025-02-13 14:50:38 -0600 | Rating Details | |
| 2025-02-13 14:50:17 -0600 | Rating Details | |
| 2025-02-13 14:50:06 -0600 | Rating Details | |
| 2025-02-13 14:49:11 -0600 | Rating Details | |
| 2025-02-13 14:43:59 -0600 | Rating Details | |
| 2025-02-13 14:38:50 -0600 | Rating Details | |
| 2025-02-13 14:31:42 -0600 | Rating Details | |
| 2025-02-13 14:17:46 -0600 | Rating Details | |
| 2025-02-13 14:07:54 -0600 | Rating Details | |
| 2025-02-15 07:00:43 -0600 | Rating Details | |
| 2025-02-14 22:37:51 -0600 | Rating Details | |
| 2025-02-14 19:34:15 -0600 | Rating Details | |
| 2025-02-15 04:59:41 -0600 | Rating Details | |
| 2025-02-14 16:58:34 -0600 | Rating Details | |
| 2025-02-14 15:58:07 -0600 | Rating Details | |
| 2025-02-14 14:45:58 -0600 | Rating Details | |
| 2025-02-14 14:37:31 -0600 | Rating Details | |
| 2025-02-14 08:50:27 -0600 | Rating Details | |
| 2025-02-14 08:09:48 -0600 | Rating Details | |
| 2025-02-14 04:07:17 -0600 | Rating Details | |
| 2025-02-14 01:22:58 -0600 | Rating Details | |
| 2025-02-13 22:08:04 -0600 | Rating Details | |
| 2025-02-13 20:33:49 -0600 | Rating Details | |
| 2025-02-13 20:21:12 -0600 | Rating Details | |
| 2025-02-13 20:08:00 -0600 | Rating Details | |
| 2025-02-13 19:22:15 -0600 | Rating Details | |
| 2025-02-13 19:20:15 -0600 | Rating Details | |
| 2025-02-13 18:19:04 -0600 | Rating Details | |
| 2025-02-13 18:08:22 -0600 | Rating Details | |
| 2025-02-13 17:19:24 -0600 | Rating Details | |
| 2025-02-13 17:09:54 -0600 | Rating Details | |
| 2025-02-13 17:09:51 -0600 | Rating Details | |
| 2025-02-13 16:27:33 -0600 | Rating Details | |
| 2025-02-13 16:02:52 -0600 | Rating Details | |
| 2025-02-13 15:53:26 -0600 | Rating Details | |
| 2025-02-13 15:45:29 -0600 | Rating Details | |
| 2025-02-13 15:35:45 -0600 | Rating Details | |
| 2025-02-13 15:19:24 -0600 | Rating Details | |
| 2025-02-13 14:52:34 -0600 | Rating Details | |
| 2025-02-13 14:50:43 -0600 | Rating Details | |
| 2025-02-13 14:19:02 -0600 | Rating Details | |
| 2025-02-27 02:56:51 -0600 | Rating Details |